Paul Cornes & Ali McBride 
Fast Facts: Biosimilars in Hematology and Oncology [EPUB ebook] 
Biologics and biosimilars – getting decisions right

Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days‘ exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. ‚Fast Facts: Biosimilars in Hematology and Oncology‘ provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients.